ライフサイエンスコーパス: followup

1 ed concurrently (baseline) and 1 year later (followup).

2 responded to 2 surveys (baseline and 6-month followup).

3 uring the followup period (mean 2.3 years of followup).

4 The effect was sustained throughout followup.

5 at baseline, and were age <65 years at last followup.

6 lower disease activity across the 2 years of followup.

7 easure (FIM) Instrument, at discharge and at followup.

8 cohort to 722 controls who were employed at followup.

9 was the modified New York criteria for AS at followup.

10 eaths (5%) during the 14,262 person-years of followup.

11 l analysis of therapy discontinuation during followup.

12 se onset and for the first 5 and 10 years of followup.

13 e adults at the time of diagnosis and during followup.

14 r functional status ratings at discharge and followup.

15 E, but none of the children, died during the followup.

16 led a DMARD prescription during 12 months of followup.

17 es in the same sample at 4-month and 8-month followup.

18 ngly associated with lower mental QOL during followup.

19 ore (MRSS) changes over the first 3 years of followup.

20 ated to back pain were collected at 12-month followup.

21 through 2005, during 89,710 person-years of followup.

22 h unilateral exudative AMD and >/=3 years of followup.

23 essive symptoms or other outcomes at 2-month followup.

24 hed control subjects had a K/L score of 0 at followup.

25 rrelations at baseline, 4-month, and 8-month followup.

26 age lesions at baseline and worsening during followup.

27 revious report during 29,314 person-years of followup.

28 line but presence of knee pain both times at followup.

29 of whom 2,460 experienced a fracture during followup.

30 and DMARD therapy of similar efficacy during followup.

31 n fatigue reduction of 25-36% for the entire followup.

32 9% remained the same or increased in size at followup.

33 ratings, total hip replacement, and time to followup.

34 nt remained on the new therapy by the end of followup.

35 of both knees was performed at baseline and followup.

36 25 men meeting no or only 1 RP criterion at followup.

37 type of stroke, length of stay, and time to followup.

38 positive in 1 deaf ear, becoming negative at followup.

39 obtained at baseline and at 15- and 30-month followup.

40 One patient was lost to followup.

41 graphic hip OA was identified at baseline or followup.

42 d potential lymphoma cases received detailed followup.

43 alignment; 227 (99.6%) completed a 30-month followup.

44 MTX for 54 weeks, with an additional year of followup.

45 tal knee replacement (TKR) in either knee at followup.

46 itis symptoms were maintained at the 6-month followup.

47 ubjects who maintained normal BMI throughout followup.

48 len joint counts during the first 2 years of followup.

49 ime of cohort entry and prospectively during followup.

50 ed incident or worsening cartilage damage at followup.

51 longed period of remission during subsequent followup.

52 August 2003 and November 2006 with 36-month followup.

53 n after 1945 and who had not used OCs during followup.

54 erse events (AEs), and 1 patient was lost to followup.

55 83 +/- 3.49 (N = 79, P = 0.0261) at the last followup.

56 vels returning toward baseline values during followup.

57 development of malignancy during post-trial followup.

58 60,362 children with 477,050 person-years of followup.

59 t undergone menopause or hysterectomy during followup.

60 , and less frequently needed therapy at last followup.

61 o receive etanercept had reduced symptoms at followup.

62 g the 8-week treatment phase, and at 6-month followup.

63 d 8,503 children with 13,990 person-years of followup.

64 Fit and Strong! program, and at the 6-month followup.

65 knee pain and better physical function over followup.

66 n whose outcomes were determined at clinical followup.

67 d between treatment groups on day 140 and at followup.

68 ce, including limited opportunity to provide followup.

69 ed quadriceps strength scores at the 2-month followup.

70 symptom onset (difference in score at 5-year followup -0.35; 95% confidence interval [95% CI] -0.51,

71 at both early and later followup (SMR 5-year followup 1.93 [95% confidence interval 1.08-3.19]; SMR 1

72 l minority of SLE patients during short-term followup (10% per year on average).

73 s were followed up from 1955 to 2000 (median followup 11.8 years).

74 During 2 years of followup, 11 patients with scleroderma (38%), 23 with IP

75 For the current followup (12.64 years postdiagnosis), 45 participants wi

76 During followup, 12.9% of women with baseline RHOA underwent TH

77 of the knee was performed at baseline and at followup (15 and/or 30 months) in 258 subjects with symp

78 evaluated every 2 months (mean +/- SD total followup 18.5 +/- 8.5 months), and patients recorded the

79 a measured at baseline (1990-1997) and first followup (1999-2003) were analyzed.

80 at baseline, immediately postprogram, and at followup 2 months after the conclusion of the interventi

81 confidence interval 1.08-3.19]; SMR 10-year followup 2.00 [95% confidence interval 1.37-2.80]).

82 Over 28 years of followup (2.9 million person-years), 8,169 cardiovascula

83 sonance imaging performed at baseline and at followup, 2 musculoskeletal radiologists blinded to the

84 veloped OA (Kellgren/Lawrence grade>or=2) at followup (2002-2005 examination) (mean of 8.75 years bet

85 men, during 26 (NHS) and 14 (NHSII) years of followup, 222 incident SLE cases were confirmed (136 NHS

86 PAP increased from baseline (20.2 mm Hg) to followup (24.3 mm Hg) (P<0.05 by Student's t-test).

87 479 JIA patients with 13,003 person-years of followup; 36% took MTX and 16% took TNF inhibitors.

88 artial remission after 1 cycle of BCDT (mean followup 39.6 months).

89 At the 6-year followup, 55 subjects had established OA (K/L score 3),

90 Over 20,936 person-years of followup, 57 subjects were clinically recognized with ne

91 During followup, 666 patients (12%) died.

92 years apart) and who were followed up (mean followup 7.1 years from the time of the second radiograp

93 During followup, 751 of them (74%) satisfied the American Colle

94 Over a mean 15 months of followup, 841 patients stopped taking the first drug due

95 rovement in FIM scores between admission and followup (95% CI 0.62, 2.12).

96 e following measures at baseline and 1-month followup: ACR-SLE battery, perceived cognitive difficult

97 at incidence who experienced low BMI during followup also had a higher risk of cardiovascular death

98 physical functioning at baseline and 1-year followup among patients with fibromyalgia syndrome (FMS)

99 erwent carotid ultrasound at baseline and at followup, an average of 4.19 years later.

100 NFalpha cohort during 13,233 person-years of followup and 17 MIs occurred in the DMARD cohort during

101 hey were randomized trials with a >or=6-week followup and if they used noninvasive outcome measures o

102 ivariate model, worsening oxygenation during followup and reduced renal function were the only signif

103 ral radiographic knee OA (case knees) during followup, and matching them each to 2 random control kne

104 lying inflammatory arthritis at baseline nor followup, and no baseline knee pain.

105 mployment loss, or loss attributed to RA, at followup as predicted by use of an anti-TNF agent at bas

106 en walking barefoot (P = 0.002 for the whole followup), as compared to these values at baseline under

107 ine and at regular clinic reviews and annual followup assessments in 232 patients from 14 centers acr

108 Baseline and 30-month followup assessments included knee magnetic resonance im

109 e interviewed and examined at baseline, with followup at 1, 2, 3, and 5 years.

110 Of the 45 patients available for followup at 6 months, 19 patients (42%) achieved remissi

111 There was 93% followup at 6 months.

112 ond set of PFTs and had abnormal findings on followup BAL fluid analysis.

113 Study followup began after a 6-month lag period to exclude pre

114 t predict quadriceps strength at the 2-month followup (beta = -0.04, P = 0.18).

115 ease in the number of activities affected at followup (beta = 0.11, P < 0.05); greater use of perseve

116 the change in C-Log scores from baseline to followup between the 2 groups (P = 0.582).

117 was a significant direct association between followup body mass and peak followup values of compressi

118 ed to predict followup kinetic values, using followup body mass as the primary explanatory variable.

119 body mass was used as a covariate, and thus followup body mass was a surrogate measure for change in

120 had BMLs at baseline, with enlarging BMLs at followup, but among the subset of knees with no BMLs at

121 Functional status was reassessed at followup by postal questionnaire.

122 Over followup, cases who had THA reported a median improvemen

123 The followup converted 83% of prior "non-users" to "users" w

124 gnetic resonance imaging, 2) availability of followup CRP level and/or ESR with radiographic imaging

125 At followup, cSLE subjects had lower overall disease activi

126 Analysis of followup data identified patients who met prespecified c

127 Examination of 2-year followup data suggested that many candidate definitions

128 Post-trial followup data were available for 153 patients (85% of th

129 Complete followup data were available from 178 children, of whom

130 Among the 13 patients for whom followup data were available, 1 patient experienced no r

131 Up to 46 months of followup data were included.

132 Baseline and 1-year followup data were obtained via structured 1-hour teleph

133 tients with knee OA (2,301 with longitudinal followup data) who were ages 45-79 years at baseline.

134 Among the 489 women with complete followup data, the median age at baseline was 52 years (

135 ssion ratio (MPR): the proportion of the 365 followup days covered by days supply.

136 At followup, despite significant improvements in clinical o

137 The mean postoperative followup duration was 20.6 +/- 7.8 months (3-32).

138 d into overall mortality (during 10 years of followup), early mortality (occurring within 2 years of

139 he DMARD cohort during 2,893 person-years of followup, equivalent to a rate of 4.8 events per 1,000 p

140 s after diagnosis; 77 patients had a 6-month followup evaluation, and 55 had a final assessment a med

141 At a 9-month followup evaluation, BF/CBT continued to exhibit relativ

142 aCL at baseline and remained so at the last followup evaluation.

143 se activity were assessed at the initial and followup evaluations with use of the Childhood Health As

144 f 1,279 subjects underwent both baseline and followup examinations (mean age at baseline 53.2 years).

145 the time of the long limb radiograph and at followup examinations.

146 iated with lower weekly rehabilitation gain, followup FIM ratings, and percentage discharged home.

147 e Measure [FIM Instrument]) at discharge and followup, FIM gain during and after rehabilitation, leng

148 tay, FIM Instrument ratings at discharge and followup, functional gain, and percentage of patients di

149 nts, at 3 months in 27%, and at >6 months of followup in 11%.

150 at diagnosis, at baseline interview, and at followup in 2004.

151 scores for MTX use at study entry and during followup in a time-varying manner; these scores were inc

152 ated with lower FIM ratings at discharge and followup in multivariate analyses.

153 nificant improvement from pretest to 6-month followup in pain (6.0 versus 3.4); self efficacy (5.5 ve

154 The overall median duration of followup in the cohort was 73.8 months (range 10.8-111.3

155 There were 9,445 and 50,803 person-years of followup in the DMARD and anti-TNF cohorts, respectively

156 Outcomes were evaluated at a median followup interval of 14.5 months.

157 Between diagnosis and followup interview, the proportion employed declined fro

158 rience a flare in the next 5 years and close followup is recommended.

159 ed regression models were created to predict followup kinetic values, using followup body mass as the

160 At followup, levels of 1,25-dihydroxyvitamin D3, PTH, OC, a

161 completion of therapy, and during long-term followup (mean +/- SD 3.6 +/- 1.94 years).

162 0; P < 0.001), but with lower FIM ratings at followup (mean +/- SD 97.7 +/- 24.7 versus 99.7 +/- 24.9

163 r HAQ scores over time than no OC use during followup (mean difference -0.06; 95% CI -0.16, 0.03); ho

164 tion study were evaluated during a long-term followup (mean followup period 41 months).

165 At the last followup (median of 44 months), relapses had occurred in

166 d knee magnetic resonance imaging (MRI) with followup MRI at 15 and 30 months.

167 Fourteen patients had followup MRI studies of the TMJ 6-12 months after inject

168 vement of 23 TMJs in the 14 patients who had followup MRI studies; resolution of effusions was observ

169 Cases were subjects who were not employed at followup (n = 231) and were matched approximately 3:1 by

170 In the investigation analyzing OC use during followup, OC use during followup was associated with low

171 During an average followup of 10 years, 106 cases of definite RA occurred,

172 CD56+ lymphocyte counts measured at a median followup of 11.8 years from the first administration of

173 d 30-month radiographs, resulting in loss to followup of 14.8% of randomized subjects.

174 During a mean followup of 15 years, 354 patients died and cardiovascul

175 ithout HF at incidence/index date had a mean followup of 15.1 and 17.0 years, respectively.

176 With a median followup of 17 and 24 months, the 2-year progression-fre

177 In a prospective study with a median followup of 24 months, 11 patients with active or refrac

178 During a mean +/- SD followup of 27 +/- 11.8 months, the direct cost of care

179 uctive status was determined after a minimum followup of 3 years after CYC therapy.

180 With a median followup of 34 months in the survivors, the actuarial 2-

181 Over a mean followup of 4.1 years, individuals in this cohort utiliz

182 licated by an infection during a mean +/- SD followup of 4.3 +/- 2.4 years.

183 to develop features of myositis after a mean followup of 4.5 years (range 2.5-6 years).

184 identified 2,298 patients with a consecutive followup of 5 years.

185 acetate, or placebo (n = 7,809), with a mean followup of 5.6 years.

186 5,076), or placebo (n = 5,196), with a mean followup of 7.1 years.

187 ical records, were ascertained over a median followup of 7.6 years.

188 7 years (68% women) and an average length of followup of 9.6+/-6.9 years.

189 in clinical remission off medication during followup of at least 4 years.

190 with other approaches for the assessment and followup of patients with TA, and has potential to ident

191 lignancy remained increased during long-term followup of the WGET cohort.

192 During followup of this cohort, 946 patients were hospitalized

193 increases in cartilage or meniscus scores at followup on the Whole-Organ Magnetic Resonance Imaging S

194 [95% CI] 1.0-3.6) and short doctor visits at followup (OR 5.6, 95% CI 2.4-13.1).

195 tomatic but developed symptomatic SLE during followup (OR 5.83, P = 0.0024).

196 , a multicenter, inception cohort study with followup over 18 years.

197 ccurred within the OA group from baseline to followup (P < 0.0001 for mode 1 and P = 0.002 for mode 6

198 an baseline IOP at 1, 3, 6, and 12 months of followup (P < 0.01).

199 eline to a median score of 6 (range 4-11) at followup (P = 0.002).

200 re and experienced little improvement during followup (P = 0.003).

201 d, it was still significant after 3 weeks of followup (P = 0.004).

202 knee pain and better physical function over followup (P<0.001).

203 Over the 6 months of followup, participants also experienced an 11% reduction

204 During long-term followup, patients with persistent alveolitis had a decl

205 e every 2 years for breast cancer during the followup period (mean 2.3 years of followup).

206 for 21 weeks, with a 13-week treatment-free followup period (week 38).

207 d to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 receive

208 were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspiri

209 evaluated during a long-term followup (mean followup period 41 months).

210 models in which we varied the length of the followup period by using different definitions of the da

211 al of 143 patients were included with a mean followup period of 4 years.

212 ciated with incident knee OA over an average followup period of 6.3 years.

213 higher rates of CVD mortality throughout the followup period studied, and this was highest in seropos

214 At the end of the followup period, 132 (32.9%) of 401 patients had died.

215 e treated with methotrexate (MTX) during the followup period, median serum MMP-3 levels decreased aft

216 During a 10-year followup period, patients continued to receive etanercep

217 further 13 patients developed ESRF over the followup period, with 10 undergoing renal transplantatio

218 ose cohorts and was sustained throughout the followup period.

219 treatment by rheumatologists over a 6-month followup period.

220 were rare: only 1 occurred during the 4-year followup period.

221 showed increased amyloid deposition over the followup period.

222 ue prevalence was 31% at baseline and 40% at followup; plaque progression occurred in 27% of the pati

223 These prospective data with long-term followup provide evidence that higher levels of serum ur

224 ther GPRD characteristics: >1 RA code during followup, RA diagnostic Group 1 or 2, and no later alter

225 (63% versus 47%; P = 0.0001); by 5 years of followup, RA estimates were approximately equal (69% ver

226 ), and keratan sulfate (KS) and baseline and followup radiographs were available for 353 knees withou

227 ison cohort (9,868 and 1,352 person-years of followup, respectively).

228 subjects (37.1% versus 27.7% at 30 years of followup, respectively; P < 0.001).

229 baseline (rho = 0.30, P < 0.01) and 2-month followup (rho = 0.23, P = 0.01).

230 There was a followup safety visit at week 28.

231 clinical protocols and for whom baseline and followup serum samples were available.

232 rams involved 8 sessions over 4 weeks with 2 followup sessions over a 6-month period, and were conduc

233 During followup, significant changes in shape of the proximal f

234 tality was increased at both early and later followup (SMR 5-year followup 1.93 [95% confidence inter

235 ort recruitment efforts may be required, and followup studies assessing the effects of these efforts

236 ation with SLE and providing a direction for followup studies.

237 5 (MTX baseline studies; 41%), and QI-6 (MTX followup studies; 46%).

238 However, the US Health Professionals Followup Study reported an inverse association between o

239 This followup study showed that individuals were more likely

240 total of 241 subjects (94.9%) completed the followup study, and 28 (11.6%) reported the new onset of

241 At 15 months' followup, subjects were again queried twice about freque

242 ificant increases in adoption after a simple followup survey (p = 0.001).

243 n of the initial study, patients completed a followup survey and were evaluated to determine the long

244 The followup survey contained questions on postvisit unmet e

245 ntion clinics for 12 months, and conducted a followup survey of 2361 intervention and 1033 comparison

246 the 141 participants, 118 completed 6-month followup testing.

247 ritten pretest, 6-week posttest, and 6-month followup tests measured pain rating, self-report joint c

248 ymptom onset had lower HAQ scores throughout followup than patients who had not taken OCs before symp

249 y better mean DAS28 values across 2 years of followup than those who were less adherent (3.28 versus

250 At followup, the average FIM rating for patients with RA wa

251 After 30 years of followup, the cumulative incidence of CHF was 34.0% in p

252 At the end of the followup, the mean SDI scores in those with childhood-on

253 ough 3 of the 8 patients had relapses during followup, the overall outcome was favorable.

254 After six months of followup, the postoperative MRSE within 0.50 D in 56% (9

255 During 15 years of followup, the prevalence of RKOA (K/L grade >or=2) incre

256 During followup, the risk of damage was higher for those who we

257 During followup, there was an excess of 123 deaths among patien

258 ith baseline acuity assessments and 30-month followup, there were no strong associations between prop

259 The observation time (followup time in the cohort) was the interval between ti

260 cohort included 7,812 children with a total followup time of 12,614 person-years; 1,484 of these chi

261 Over a median followup time of 17 months, the rate of hospitalization

262 (85% of the original cohort), with a median followup time of 43 months.

263 Median followup time was 4.4 person-years.

264 Median followup time was 4.4 years (range 2.7-7.4 years).

265 Median followup time was 47 months (range 0-54).

266 Age, sex, ethnicity, followup time, and all known risk factors for the occurr

267 re older age, current smoking status, longer followup time, elevated serum levels of C-reactive prote

268 Median followup times were 3.4 years for the AAV patients and 4

269 een the years 1973 and 2002, with additional followup to 2004.

270 Limiting followup to the first 90 days, however, revealed an adju

271 At study entry and during followup, total Sharp scores (TSS), RA-associated joint

272 sequent GalNAc additions were carried out by followup transferases, in particular GalNAc-T10.

273 reased by >or= 1 units at the last available followup, using a modified Whole-Organ MRI Score.

274 medial joint space loss between baseline and followup, using linear regression with generalized estim

275 ociation between followup body mass and peak followup values of compressive force (P = 0.001), result

276 itially enrolled, 31 returned for at least 1 followup visit and were included in the analysis (modifi

277 ed on the damage score at the last available followup visit.

278 However, the frequency of followup visits at which the subject reported a > or = 2

279 crease in knee pain at the majority of their followup visits had more rapid JSN than those whose pain

280 At baseline and at followup visits, knee pain was assessed using a visual a

281 At the 5 semiannual followup visits, the mean TIINE concentration for doxycy

282 The double-blind phase entailed 15 bimonthly followup visits; intervisit adherence data were download

283 The median duration of followup was >44 months, and the rate of visit complianc

284 The median followup was 10.1 years (interquartile range 9.3-10.8).

285 -onset SLE were female; the mean duration of followup was 3.2 and 3.5 years, respectively.

286 nd 13.4 years, respectively, and mean age at followup was 30.5 and 49.9 years, respectively.

287 The median followup was 4.9 years.

288 The mean duration of followup was 54.7 weeks (SD 39.2 weeks).

289 The mean followup was 57.1 +/- 29.0 months (range 13.8-150.6 mont

290 OC use during followup was additionally investigated in 265 women who

291 lyzing OC use during followup, OC use during followup was associated with lower HAQ scores over time

292 Information on 3,184 patient-months of followup was included in the analysis.

293 e Activity Score in 28 joints at 6 months of followup was the outcome measure.

294 At baseline and the 30-month followup, we assessed the presence of frequent pain, obt

295 es in VLA disability from baseline to 1-year followup were assessed.

296 ine; cases were consistently not employed at followup, whereas controls remained employed.

297 ly associated with lower physical QOL during followup, whereas erythrocyte sedimentation rate was mos

298 ,591 RA patients over 89,710 person-years of followup, which included exposure to anti-TNF therapy in

299 iographic evidence of incident hip OA during followup, while controls (n = 601) were subjects in whom

300 Followup work by Calderon et al. clustered and computati